EBLN2

Across TCGA pan-cancer cohorts, EBLN2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EBLN2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher EBLN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EBLN2 expression acts as an unfavorable survival marker.

SKCM and COAD are the cancer types where EBLN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.230	0.781	.004	18	view →
COAD	OS	Median	IV	0.089	0.649	.005	14	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

EBLN2–SKCM (OS)

Open the SKCM breakdown →